Malaria transmission after artemether-lumefantrine and dihydroartemisinin- piperaquine: A randomized trial

Journal of Infectious Diseases

Volumn 207, Issue 11, 2013, Pages 1637-1645

  Sawa, Patrick ^a   Shekalaghe, Seif A ^c,d   Drakeley, Chris J ^e   Sutherland, Colin J ^e   Mweresa, Collins K ^a   Baidjoe, Amrish Y ^g   Manjurano, Alphaxard ^c   Kavishe, Reginald A ^c   Beshir, Khalid B ^e   Yussuf, Rahma U ^b   Omar, Sabah A ^b   Hermsen, Cornelus C ^g   Okell, Lucy ^f   Schallig, Henk D F H ^h   Sauerwein, Robert W ^g   Hallett, Rachel L ^e   Bousema, Teun ^e,g  

^a INTERNATIONAL CENTRE OF INSECT PHYSIOLOGY AND ECOLOGY ICIPE   (Kenya)

^b KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

^c KILIMANJARO CHRISTIAN MEDICAL CENTRE   (Tanzania)

^d IFAKARA HEALTH INSTITUTE   (Tanzania)

^e LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^f IMPERIAL COLLEGE LONDON   (United Kingdom)

^g RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^h ROYAL TROPICAL INSTITUTE   (Netherlands)

Author keywords

anopheles; artemisinin; coartem; falciparum; gametocyte; genotyping; malaria; mosquito; recrudescence; transmission

Indexed keywords

ARTEMETHER PLUS BENFLUMETOL; DIHYDROARTEMISININ PLUS PIPERAQUINE; DUOCOTEXIN; UNCLASSIFIED DRUG;

ARTICLE; BLOOD SAMPLING; CHILD; CONTROLLED STUDY; DRUG EFFICACY; DRUG TREATMENT FAILURE; GAMETOCYTE; GENOTYPE; HUMAN; INFANT; KENYA; MAJOR CLINICAL STUDY; MALARIA; PARASITE IDENTIFICATION; PARASITE VIRULENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; RECURRENT INFECTION; SCHOOL CHILD; TREATMENT RESPONSE;

ANIMALS; ARTEMISININS; CHILD; CHILD, PRESCHOOL; CULICIDAE; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; ETHANOLAMINES; FEMALE; FLUORENES; HUMANS; INFANT; KENYA; MALARIA, FALCIPARUM; MALE; PLASMODIUM FALCIPARUM; POLYMERASE CHAIN REACTION; QUINOLINES; RECURRENCE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84877311728     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jit077     Document Type: Article

References (43)

1. Phyo AP, Nkhoma S, Stepniewska K, et al. Emergence of artemisininresistant malaria on the western border of Thailand: a longitudinal study. Lancet 2012; 379:1960-6.
2. Dondorp AM, Nosten F, Yi P, et al. Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med 2009; 361:455-67.
3. 4ABC Study Group. A head-to-head comparison of four artemisininbased combinations for treating uncomplicated malaria in African children: a randomized trial. PLoS Med 2011; 8:e1001119.
4. Bousema JT, Schneider P, Gouagna LC, et al. Moderate effect of artemisinin-based combination therapy on transmission of Plasmodium falciparum. J Infect Dis 2006; 193:1151-9.
5. Sutherland CJ, Ord R, Dunyo S, et al. Reduction of malaria transmission to anopheles mosquitoes with a six-dose regimen of coartemether. PLoS Med 2005; 2:e92.
6. Targett G, Drakeley C, Jawara M, et al. Artesunate reduces but does not prevent posttreatment transmission of Plasmodium falciparum to Anopheles gambiae. J Infect Dis 2001; 183:1254-9.
7. Barnes KI, Chanda P, Ab Barnabas G. Impact of the large-scale deployment of artemether/lumefantrine on the malaria disease burden in Africa: case studies of South Africa, Zambia and Ethiopia. Malar J 2009; 8(Suppl 1):S8.
8. Barnes KI, Durrheim DN, Little F, et al. Effect of artemetherlumefantrine policy and improved vector control on malaria burden in KwaZulu-Natal, South Africa. PLoS Med 2005; 2:e330.
9. Bhattarai A, Ali AS, Kachur SP, et al. Impact of artemisinin-based combination therapy and insecticide-treated nets on malaria burden in Zanzibar. PLoS Med 2007; 4:e309.
10. Price RN, Nosten F, Luxemburger C, et al. Effects of artemisinin derivatives on malaria transmissibility. Lancet 1996; 347:1654-8.
11. Okell LC, Drakeley CJ, Ghani AC, Bousema T, Sutherland CJ. Reduction of transmission from malaria patients by artemisinin combination therapies: a pooled analysis of six randomized trials. Malar J 2008; 7:125.
12. Bassat Q, Mulenga M, Tinto H, et al. Dihydroartemisinin-piperaquine and artemether-lumefantrine for treating uncomplicated malaria in African children: a randomised, non-inferiority trial. PLoS One 2009; 4:e7871.
13. Yeka A, Dorsey G, Kamya MR, et al. Artemether-lumefantrine versus dihydroartemisinin-piperaquine for treating uncomplicated malaria: a randomized trial to guide policy in Uganda. PLoS One 2008; 3:e2390.
14. Mens PF, Sawa P, van Amsterdam SM, et al. A randomized trial to monitor the efficacy and effectiveness by QT-NASBA of artemetherlumefantrine versus dihydroartemisinin-piperaquine for treatment and transmission control of uncomplicated Plasmodium falciparum malaria in western Kenya. Malar J 2008; 7:237.
15. Arinaitwe E, Sandison TG, Wanzira H, et al. Artemether-lumefantrine versus dihydroartemisinin-piperaquine for falciparum malaria: a longitudinal, randomized trial in young Ugandan children. Clin Infect Dis 2009; 49:1629-37.
16. Smithuis F, Kyaw MK, Phe O, et al. Effectiveness of five artemisinin combination regimens with or without primaquine in uncomplicated falciparum malaria: an open-label randomised trial. Lancet Infect Dis 2010; 10:673-81.
17. Bousema T, Drakeley C. Epidemiology and infectivity of Plasmodium falciparum and Plasmodium vivax gametocytes in relation to malaria control and elimination. Clin Microbiol Rev 2011; 24:377-410.
18. Boudin C, Olivier M, Molez JF, Chiron JP, Ambroise-Thomas P. High human malarial infectivity to laboratory-bred Anopheles gambiae in a village in Burkina Faso. Am J Trop Med Hyg 1993; 48:700-6.
19. Ouedraogo AL, Bousema T, Schneider P, et al. Substantial contribution of submicroscopical Plasmodium falciparum gametocyte carriage to the infectious reservoir in an area of seasonal transmission. PLoS One 2009; 4:e8410.
20. Schneider P, Bousema JT, Gouagna LC, et al. Submicroscopic Plasmodium falciparum gametocyte densities frequently result in mosquito infection. Am J Trop Med Hyg 2007; 76:470-4.
21. Fofana B, Djimde AA, Sagara I, et al. Impact of artemisinin-based combination therapy on malaria transmission in Mali [abstract MIM16762172]. In: Program and abstracts of the 5th MIM Pan-African Malaria Conference, Nairobi, Kenya, 2-6 November 2009: 5.
22. Hallett RL, Dunyo S, Ord R, et al. Chloroquine/sulphadoxinepyrimethamine for Gambian children with malaria: transmission to mosquitoes of multidrug-resistant Plasmodium falciparum. PLoS Clin Trials 2006; 1:e15.
23. Beavogui AH, Djimde AA, Gregson A, et al. Low infectivity of Plasmodium falciparum gametocytes to Anopheles gambiae following treatment with sulfadoxine-pyrimethamine in Mali. Int J Parasitol 2010; 40:1213-20.
24. Kaur H, Goodman C, Thompson E, et al. A nationwide survey of the quality of antimalarials in retail outlets in Tanzania. PLoS One 2008; 3: e3403.
25. Schneider P, Schoone G, Schallig H, et al. Quantification of Plasmodium falciparum gametocytes in differential stages of development by quantitative nucleic acid sequence-based amplification. Mol Biochem Parasitol 2004; 137:35-41.
26. Snounou G, Zhu X, Siripoon N, et al. Biased distribution of msp1 and msp2 allelic variants in Plasmodium falciparum populations in Thailand. Trans R Soc Trop Med Hyg 1999; 93:369-74.
27. Plowe CV, Djimde A, Bouare M, Doumbo O, Wellems TE. Pyrimethamine and proguanil resistance-conferring mutations in Plasmodium falciparum dihydrofolate reductase: polymerase chain reaction methods for surveillance in Africa. Am J Trop Med Hyg 1995; 52: 565-8.
28. World Health Organization (WHO). Genotyping to identify parasite populations. Geneva: WHO, 2008.
29. Waitumbi JN, Anyona SB, Hunja CW, et al. Impact of RTS,S/AS02(A) and RTS,S/AS01(B) on genotypes of P. falciparum in adults participating in a malaria vaccine clinical trial. PLoS One 2009; 4:e7849.
30. Bukirwa H, Yeka A, Kamya MR, et al. Artemisinin combination therapies for treatment of uncomplicated malaria in Uganda. PLoS Clin Trials 2006; 1:e7.
31. Bousema T, Okell L, Shekalaghe S, et al. Revisiting the circulation time of Plasmodium falciparum gametocytes: molecular detection methods to estimate the duration of gametocyte carriage and the effect of gametocytocidal drugs. Malar J 2010; 9:136.
32. Price RN, Hasugian AR, Ratcliff A, et al. Clinical and pharmacological determinants of the therapeutic response to dihydroartemisinin-piperaquine for drug-resistant malaria. Antimicrob Agents Chemother 2007; 51:4090-7.
33. Ashley EA, Krudsood S, Phaiphun L, et al. Randomized, controlled dose-optimization studies of dihydroartemisinin-piperaquine for the treatment of uncomplicated multidrug-resistant falciparum malaria in Thailand. J Infect Dis 2004; 190:1773-82.
34. Hung TY, Davis TM, Ilett KF, et al. Population pharmacokinetics of piperaquine in adults and children with uncomplicated falciparum or vivax malaria. Br J Clin Pharmacol 2004; 57:253-62.
35. Ezzet F, van Vugt M, Nosten F, Looareesuwan S, White NJ. Pharmacokinetics and pharmacodynamics of lumefantrine (benflumetol) in acute falciparum malaria. Antimicrob Agents Chemother 2000; 44:697-704.
36. Price RN, Douglas NM. Artemisinin combination therapy for malaria: beyond good efficacy. Clin Infect Dis 2009; 49:1638-40.
37. Stepniewska K, White NJ. Pharmacokinetic determinants of the window of selection for antimalarial drug resistance. Antimicrob Agents Chemother 2008; 52:1589-96.
38. Pongtavornpinyo W, Yeung S, Hastings IM, Dondorp AM, Day NP, White NJ. Spread of anti-malarial drug resistance: mathematical model with implications for ACT drug policies. Malar J 2008; 7:229.
39. Okell LC, Drakeley CJ, Bousema T, Whitty CJ, Ghani AC. Modelling the impact of artemisinin combination therapy and long-acting treatments on malaria transmission intensity. PLoS Med 2008; 5:e226; discussion e226.
40. Adjalley SH, Johnston GL, Li T, et al. Quantitative assessment of Plasmodium falciparum sexual development reveals potent transmissionblocking activity by methylene blue. Proc Natl Acad Sci USA 2011; 108:E1214-23.
41. van Pelt-Koops JC, Pett HE, Graumans W, et al. The spiroindolone drug candidate NITD609 potently inhibits gametocytogenesis and blocks Plasmodium falciparum transmission to Anopheles mosquito vector. Antimicrob Agents Chemother 2012; 56:3544-8.
42. White NJ. Qinghaosu (artemisinin): the price of success. Science 2008; 320:330-4.
43. Ratcliff A, Siswantoro H, Kenangalem E, et al. Two fixed-dose artemisinin combinations for drug-resistant falciparum and vivax malaria in Papua, Indonesia: an open-label randomised comparison. Lancet 2007; 369:757-65.